| Interactions between Borrelia burgdorferi and ticks C Kurokawa, GE Lynn, JHF Pedra, U Pal, S Narasimhan, E Fikrig Nature Reviews Microbiology 18 (10), 587-600, 2020 | 149 | 2020 |
| Immunovirotherapy with measles virus strains in combination with anti–PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment J Hardcastle, L Mills, CS Malo, F Jin, C Kurokawa, H Geekiyanage, ... Neuro-oncology 19 (4), 493-502, 2017 | 129 | 2017 |
| Constitutive interferon pathway activation in tumors as an efficacy determinant following oncolytic virotherapy C Kurokawa, ID Iankov, SK Anderson, I Aderca, AA Leontovich, ... JNCI: Journal of the National Cancer Institute 110 (10), 1123-1132, 2018 | 100 | 2018 |
| mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent A Sajid, J Matias, G Arora, C Kurokawa, K DePonte, X Tang, G Lynn, ... Science translational medicine 13 (620), eabj9827, 2021 | 83 | 2021 |
| A key anti-viral protein, RSAD2/VIPERIN, restricts the release of measles virus from infected cells C Kurokawa, ID Iankov, E Galanis Virus research 263, 145-150, 2019 | 66 | 2019 |
| Immunostimulatory bacterial antigen–armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy E Panagioti, C Kurokawa, K Viker, A Ammayappan, SK Anderson, ... The Journal of clinical investigation 131 (13), 2021 | 39 | 2021 |
| Ixodes scapularis saliva components that elicit responses associated with acquired tick-resistance S Narasimhan, C Kurokawa, H Diktas, NO Strank, J Černý, K Murfin, ... Ticks and tick-borne diseases 11 (3), 101369, 2020 | 38 | 2020 |
| Acquired tick resistance: The trail is hot S Narasimhan, C Kurokawa, M DeBlasio, J Matias, A Sajid, U Pal, G Lynn, ... Parasite immunology 43 (5), e12808, 2021 | 34 | 2021 |
| Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma C Kurokawa, H Geekiyanage, C Allen, I Iankov, M Schroeder, B Carlson, ... Journal of neuro-oncology 131, 41-48, 2017 | 31 | 2017 |
| Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells M Opyrchal, M Gil, JL Salisbury, MP Goetz, V Suman, A Degnim, ... Oncotarget 8 (53), 91803, 2017 | 26 | 2017 |
| Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy ID Iankov, CB Kurokawa, AB D'Assoro, JN Ingle, E Domingo-Musibay, ... Cancer gene therapy 22 (9), 438-444, 2015 | 25 | 2015 |
| Repeat tick exposure elicits distinct immune responses in guinea pigs and mice C Kurokawa, S Narasimhan, A Vidyarthi, CJ Booth, S Mehta, L Meister, ... Ticks and tick-borne diseases 11 (6), 101529, 2020 | 23 | 2020 |
| Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma E Domingo-Musibay, C Allen, C Kurokawa, JJ Hardcastle, I Aderca, ... Cancer gene therapy 21 (11), 483-490, 2014 | 21 | 2014 |
| Tick immunity using mRNA, DNA and protein-based Salp14 delivery strategies J Matias, C Kurokawa, A Sajid, S Narasimhan, G Arora, H Diktas, GE Lynn, ... Vaccine 39 (52), 7661-7668, 2021 | 19 | 2021 |
| Interferon signaling predicts response to oncolytic virotherapy C Kurokawa, E Galanis Oncotarget 10 (16), 1544, 2019 | 8 | 2019 |
| Live attenuated measles virus vaccine expressing Helicobacter pylori heat shock protein A ID Iankov, C Kurokawa, K Viker, SI Robinson, A Ammayappan, ... Molecular Therapy-Oncolytics 19, 136-148, 2020 | 6 | 2020 |
